首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

【2h】

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

机译：恩杂鲁胺在先前接受多西他赛治疗的转移性去势抵抗性前列腺癌患者中的安全性：在北美的使用范围扩大

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUNDThe open‐label, single‐arm enzalutamide expanded access program (EAP) in the United States and Canada evaluated the safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer (mCRPC) who had previously received docetaxel.

机译：背景美国和加拿大的开放标签，单臂enzalutamide扩展访问计划（EAP）评估了enzalutamide在先前接受多西他赛治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中的安全性。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
Anthony M. Joshua; Neal D. Shore; Fred Saad; Kim N. Chi; Carl A. Olsson; Urban Emmenegger; Mark Scholz; William Berry; Som D. Mukherjee; Eric Winquist; Naomi B. Haas; Margaret A. Foley; Carl Dmuchowski; Frank Perabo; Mohammad Hirmand; Nahla Hasabou; Dana Rathkopf;
展开▼
作者单位

展开▼
年(卷),期 -1(75),8
年度 -1
页码 836–844
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
enzalutamide metastatic castration‐resistant prostate cancer expanded access program safety treatment exposure;

机译：恩杂鲁胺;转移性去势抵抗性前列腺癌;扩大准入计划;安全性;治疗暴露;
入库时间 2022-08-21 11:03:43

相似文献

外文文献
中文文献
专利

1. Safety of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel: Expanded Access in North America [J] . Joshua Anthony M., Shore Neal D., Saad Fred, The Prostate . 2015,第8期

机译：恩扎鲁胺在先前接受多西他赛治疗的转移性去势抵抗性前列腺癌患者中的安全性：在北美的普及性
2. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone [J] . BianchiniD., LorenteD., Rodriguez-VidaA., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第1期

机译：恩杂鲁胺（MDV3100）对多西他赛和阿比特龙治疗的转移性去势抵抗性前列腺癌（CRPC）患者的抗肿瘤活性
3. Clinical Outcomes and Survival Surrogacy Studies of Prostate-Specific Antigen Declines Following Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel [J] . Armstrong Andrew J., Saad Fred, Phung De, Cancer: A Journal of the American Cancer Society . 2017,第12期

机译：前列腺特异性抗原的临床结果和生存替代研究在先前用多西紫杉醇治疗的转移性阉割抗阉割前列腺癌中的男性中依齐甲酰胺下降
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study [O] . Jacob A. Gordon, Carlo Buonerba, Gregory Pond, 2018

机译：多西他赛治疗失败后用阿比特龙或恩杂鲁胺治疗转移性去势抵抗性前列腺癌患者的他汀类药物使用和生存：国际回顾性STABEN研究
7. Docetaxel–Cabazitaxel–Enzalutamide Versus Docetaxel–Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer [O] . Igor Richter, Josef Dvořák, Jiří Bartoš 2017

机译：Docetaxel-Cabazitaxel-eNzalutamide与多西紫杉醇 - 苯甲丁酰胺患者在转移性阉割的前列腺癌患者中

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

摘要

著录项

相似文献

相关主题

期刊订阅